Association of polygenic score for schizophrenia and HLA antigen and inflammation genes with response to lithium in bipolar affective disorder: A genome-wide association study

JAMA Psychiatry

Volumn 75, Issue 1, 2018, Pages 65-74

  Amare, Azmeraw T ^a   Schubert, Klaus Oliver ^a,b   Hou, Liping ^c   Clark, Scott R ^a   Papiol, Sergi ^d   Heilbronner, Urs ^d,e   Degenhardt, Franziska ^f   Tekola Ayele, Fasil ^g   Hsu, Yi Hsiang ^h,i,j   Shekhtman, Tatyana ^k   Adli, Mazda ^l   Akula, Nirmala ^c   Akiyama, Kazufumi ^m   Ardau, Raffaella ⁿ   Arias, Bárbara ^o   Aubry, Jean Michel ^p   Backlund, Lena ^q,r   Bhattacharjee, Abesh Kumar ^k   Bellivier, Frank ^s   Benabarre, Antonio ^o   Bengesser, Susanne ^t   Biernacka, Joanna M ^u   Birner, Armin ^t   Brichant Petitjean, Clara ^s   Cervantes, Pablo ^v   Chen, Hsi Chung ^w   Chillotti, Caterina ⁿ   Cichon, Sven ^f,x   Cruceanu, Cristiana ^y   Czerski, Piotr M ^z   Dalkner, Nina ^t   Dayer, Alexandre ^p   Del Zompo, Maria ⁿ   DePaulo, J Raymond ^aa   Étain, Bruno ^s   Falkai, Peter ^d   Forstner, Andreas J ^f,x,ab   Frisen, Louise ^q,r   Frye, Mark A ^u   Fullerton, Janice M ^ac,ad   Gard, Sébastien ^ae   Garnham, Julie S ^af   Goes, Fernando S ^aa   Grigoroiu Serbanescu, Maria ^ag   Grof, Paul ^ah   Hashimoto, Ryota ^ai,aj   Hauser, Joanna ^z   Herms, Stefan ^f,x   Hoffmann, Per ^f,x   Hofmann, Andrea ^f   Jamain, Stephane ^ak   Jiménez, Esther ^o   Kahn, Jean Pierre ^al   Kassem, Layla ^c   Kuo, Po Hsiu ^am   Kato, Tadafumi ^an   Kelsoe, John ^k   Kittel Schneider, Sarah ^ao   Kliwicki, Sebastian ^z   König, Barbara ^ap   Kusumi, Ichiro ^aq   Laje, Gonzalo ^c   Landén, Mikael ^q,ar   Lavebratt, Catharina ^q,r   Leboyer, Marion ^as   Leckband, Susan G ^at   Tortorella, Alfonso ^au   Manchia, Mirko ^n,af   Martinsson, Lina ^q   McCarthy, Michael J ^k,at   McElroy, Susan ^av   Colom, Francesc ^o,aw   Mitjans, Marina ^ax,ay   Mondimore, Francis M ^aa   Monteleone, Palmiero ^az,ba   Nievergelt, Caroline M ^k   Nöthen, Markus M ^f   Novák, Tomas ^bb   O'Donovan, Claire ^af   Ozaki, Norio ^bc   Ösby, Urban ^r   Pfennig, Andrea ^bd   Potash, James B ^aa   Reif, Andreas ^an   Reininghaus, Eva ^t   Rouleau, Guy A ^be   Rybakowski, Janusz K ^ao   Schalling, Martin ^q,r   Schofield, Peter R ^ac,ad   Schweizer, Barbara W ^aa   Severino, Giovanni ⁿ   Shilling, Paul D ^q,r   Shimoda, Katzutaka ^m   Simhandl, Christian ^bf   Slaney, Claire M ^af   Squassina, Alessio ⁿ   Stamm, Thomas ^l   Stopkova, Pavla ^bb   Maj, Mario ^ba   Turecki, Gustavo ^y   Vieta, Eduard ^o   Volkert, Julia ^ao   Witt, Stephanie ^bg   Wright, Adam ^bh   Zandi, Peter P ^bi   Mitchell, Philip B ^bh   Bauer, Michael ^bd   Alda, Martin ^af   Rietschel, Marcella ^bg   McMahon, Francis J ^c   Schulze, Thomas G ^c,d,e,aa,bg   Baune, Bernhard T ^a   more..

^a UNIVERSITY OF ADELAIDE   (Australia)

^b Mental Health Services   (Australia)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e UNIVERSITY OF GÖTTINGEN   (Germany)

^f UNIVERSITY OF BONN   (Germany)

^g EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^j BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^m DOKKYO MEDICAL UNIVERSITY   (Japan)

ⁿ UNIVERSITY OF CAGLIARI   (Italy)

^o UNIVERSITY OF BARCELONA   (Spain)

^p GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^q KAROLINSKA INSTITUTE   (Sweden)

^r KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^s UMR S 1144   (France)

^t MEDICAL UNIVERSITY OF GRAZ   (Austria)

^u MAYO CLINIC   (United States)

^v MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^w NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^x UNIVERSITY HOSPITAL BASEL   (Switzerland)

^y DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

^z POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^aa JOHNS HOPKINS UNIVERSITY   (United States)

^ab UNIVERSITY OF BASEL   (Switzerland)

^ac NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^ad UNIVERSITY OF NEW SOUTH WALES   (Australia)

^ae CENTRE HOSPITALIER CHARLES PERRENS   (France)

^af DALHOUSIE UNIVERSITY   (Canada)

^ag Psychiatric Hospital Bucharest   (Romania)

^ah Mood Disorders Center of Ottawa   (Canada)

^ai OSAKA UNIVERSITY   (Japan)

^aj OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^ak INSERM   (France)

^al UNIVERSITÉ DE LORRAINE   (France)

^am NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^an RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

^ao UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^ap RIKEN Brain Science Institute ^*  (Austria)

^aq HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^ar UNIVERSITY OF GOTHENBURG   (Sweden)

^as UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^at VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^au UNIVERSITY OF PERUGIA   (Italy)

^av UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^aw HOSPITAL DEL MAR   (Spain)

^ax CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^ay MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^az UNIVERSITY OF SALERNO   (Italy)

^ba SECOND UNIVERSITY OF NAPLES   (Italy)

^bb NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

^bc NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^bd UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^be MCGILL UNIVERSITY   (Canada)

^bf SIGMUND FREUD UNIVERSITY   (Austria)

^bg UNIVERSITY OF HEIDELBERG   (Germany)

^bh UNIVERSITY OF NEW SOUTH WALES   (Australia)

^bi JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HLA A ANTIGEN; HLA ANTIGEN; HLA DM ANTIGEN; HLA DMA ANTIGEN; HLA DMB ANTIGEN; HLA DO ANTIGEN; HLA DOB ANTIGEN; HLA DPB1 ANTIGEN; HLA F ANTIGEN; HLA G ANTIGEN; INTERLEUKIN 4; LITHIUM; OX40 LIGAND; PSMB9 ANTIGEN; TAP2 ANITGEN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; LITHIUM CARBONATE;

ADULT; ALLELE; ANTIGEN PRESENTATION; ARTICLE; BIPOLAR DISORDER; CLINICAL EVALUATION; CLINICAL OUTCOME; CONTROLLED STUDY; FEMALE; GENE LOCUS; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC LOAD; GENETIC PARAMETERS; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUGO GENE NOMENCLATURE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MIDDLE AGED; POLYGENIC SCORE; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; QUANTITATIVE TRAIT LOCUS; SCHIZOPHRENIA; SCORING SYSTEM; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; GENETICS; INFLAMMATION; MULTIFACTORIAL INHERITANCE; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; BIPOLAR DISORDER; FEMALE; GENETIC LOAD; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HLA ANTIGENS; HUMANS; INFLAMMATION; LITHIUM CARBONATE; MALE; MIDDLE AGED; MULTIFACTORIAL INHERITANCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 85040465816     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2017.3433     Document Type: Article

References (68)

1. Merikangas KR, Jin R, He J-P, et al. Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey initiative. Arch Gen Psychiatry. 2011;68(3):241-251.
2. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007;64 (5):543-552.
3. Ferrari AJ, Stockings E, Khoo JP, et al. The prevalence and burden of bipolar disorder: findings from the Global Burden of Disease Study 2013. Bipolar Disord. 2016;18(5):440-450.
4. Chesney E, Goodwin GM, Fazel S. Risks of all-cause and suicide mortality in mental disorders: ameta-review.World Psychiatry. 2014;13(2):153-160.
5. Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet. 2016;387(10027):1561-1572.
6. Smoller JW, Finn CT. Family, twin, and adoption studies of bipolar disorder. Am J Med Genet C Semin Med Genet. 2003;123C(1):48-58.
7. Weber H, Kittel-Schneider S, Gessner A, et al. Cross-disorder analysis of bipolar risk genes: further evidence of DGKH as a risk gene for bipolar disorder, but also unipolar depression and adult ADHD. Neuropsychopharmacology. 2011;36(10): 2076-2085.
8. Psychiatric GWAS Consortium Bipolar Disorder Working Group. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4 [published correction appears in Nat Genet. 2012;44(9):1072]. Nat Genet. 2011;43(10):977-983.
9. Ikeda M, Takahashi A, Kamatani Y, et al. A genome-wide association study identifies two novel susceptibility loci and trans population polygenicity associated with bipolar disorder [published online January 24, 2017]. Mol Psychiatry.
10. M leisen TW, Leber M, Schulze TG, et al. Genome-wide association study reveals two new risk loci for bipolar disorder. Nat Commun. 2014;5: 3339.
11. Hou L, Bergen SE, Akula N, et al. Genome-wide association study of 40, 000 individuals identifies two novel loci associated with bipolar disorder. Hum Mol Genet. 2016;25(15):3383-3394.
12. Cichon S, Mleisen TW, Degenhardt FA, et al; Bipolar Disorder Genome Study (BiGS) Consortium. Genome-wide association study identifies genetic variation in neurocan as a susceptibility factor for bipolar disorder. Am J Hum Genet. 2011;88(3): 372-381.
13. Cade JF. Lithium salts in the treatment of psychotic excitement. Med J Aust. 1949;2(10): 349-352.
14. Miura T, Noma H, Furukawa TA, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry. 2014;1(5):351-359.
15. Malhi GS, Tanious M, Das P, Berk M. The science and practice of lithium therapy.Aust N Z J Psychiatry. 2012;46(3):192-211.
16. Malhi GS, Adams D, Berk M. Is lithium in a class of its own? a brief profile of its clinical use.Aust N Z J Psychiatry. 2009;43(12):1096-1104.
17. Tondo L, Hennen J, Baldessarini RJ. Lower suicide risk with long-term lithium treatment in major affective illness: ameta-analysis. Acta Psychiatr Scand. 2001;104(3):163-172.
18. National Collaborating Centre for Mental Health. Bipolar Disorder: The Management of Bipolar Disorder in Adults, Children and Adolescents, in Primary and Secondary Care. Leicester, England: British Psychological Society; 2006.
19. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15(1):1-44.
20. Malhi GS, Bassett D, Boyce P, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2015;49(12):1087-1206.
21. Goodwin GM, Haddad PM, Ferrier IN, et al. Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2016;30(6):495-553.
22. Hou L, Heilbronner U, Degenhardt F, et al. Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet. 2016;387 (10023):1085-1093.
23. Kleindienst N, Engel RR, GreilW. Psychosocial and demographic factors associated with response to prophylactic lithium: a systematic review for bipolar disorders. Psychol Med. 2005;35(12): 1685-1694.
24. Grof P, Duffy A, Cavazzoni P, et al. Is response to prophylactic lithium a familial trait? J Clin Psychiatry. 2002;63(10):942-947.
25. Higgins GA, Allyn-Feuer A, Barbour E, Athey BD. A glutamatergic network mediates lithium response in bipolar disorder as defined by epigenome pathway analysis. Pharmacogenomics. 2015;16(14):1547-1563.
26. Song J, Bergen SE, Di Florio A, et al; Members of the International Cohort Collection for Bipolar Disorder (ICCBD). Genome-wide association study identifies SESTD1 as a novel risk gene for lithium-responsive bipolar disorder. Mol Psychiatry. 2016;21(9):1290-1297.
27. Chen CH, Lee CS, LeeMT, et al; Taiwan Bipolar Consortium. Variant GADL1 and response to lithium therapy in bipolar I disorder. N Engl J Med. 2014; 370(2):119-128.
28. Lee SH, Ripke S, Neale BM, et al; Cross-Disorder Group of the Psychiatric Genomics Consortium; International Inflammatory Bowel Disease Genetics Consortium (IIBDGC). Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet. 2013;45(9):984-994.
29. Forstner AJ, Hecker J, Hofmann A, et al. Identification of shared risk loci and pathways for bipolar disorder and schizophrenia. PLoS One. 2017; 12(2):e0171595.
30. Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet. 2013; 381(9875):1371-1379.
31. FöckingM, Dicker P, English JA, Schubert KO, Dunn MJ, Cotter DR. Common proteomic changes in the hippocampus in schizophrenia and bipolar disorder and particular evidence for involvement of cornu ammonis regions 2 and 3. Arch Gen Psychiatry. 2011;68(5):477-488.
32. Leucht S, Helfer B, Dold M, KisslingW, McGrath JJ. Lithium for schizophrenia. Cochrane Database Syst Rev. 2015;(10):CD003834.
33. Grof P, Alda M, Grof E, Zvolsky P, Walsh M. Lithium response and genetics of affective disorders. J Affect Disord. 1994;32(2):85-95.
34. Pearlson GD. Etiologic, phenomenologic, and endophenotypic overlap of schizophrenia and bipolar disorder. Annu Rev Clin Psychol. 2015;11: 251-281.
35. Sachs GS, Peters AT, Sylvia L, Grunze H. Polypharmacy and bipolar disorder: what's personality got to do with it? Int J Neuropsychopharmacol. 2014;17(7):1053-1061.
36. SchizophreniaWorking Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511(7510):421-427.
37. Schulze TG, Alda M, Adli M, et al. The International Consortium on Lithium Genetics (ConLiGen): an initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment. Neuropsychobiology. 2010;62(1):72-78.
38. Duffy A, Alda M, Milin R, Grof P. A consecutive series of treated affected offspring of parents with bipolar disorder: is response associated with the clinical profile? Can J Psychiatry. 2007;52(6): 369-376.
39. Garnham J, Munro A, Slaney C, et al. Prophylactic treatment response in bipolar disorder: results of a naturalistic observation study. J Affect Disord. 2007;104(1-3):185-190.
40. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81(3):559-575.
41. Yang Q, Wu H, Guo CY, Fox CS. Analyze multivariate phenotypes in genetic association studies by combining univariate association tests. Genet Epidemiol. 2010;34(5):444-454.
42. Yang Q, Wang Y.Methods for analyzing multivariate phenotypes in genetic association studies. J Probab Stat. 2012;2012:652569.
43. Prien RJ. Lithium in the treatment of schizophrenia and schizoaffective disorders. Arch Gen Psychiatry. 1979;36(8 spec no):852-853.
44. Shopsin B, Kim SS, Gershon S. A controlled study of lithium vs. chlorpromazine in acute schizophrenics. Br J Psychiatry. 1971;119(551): 435-440.
45. Silva LFAL, Loureiro JC, Franco SCR, et al. Assessing treatment response to prophylactic lithium use in patients with bipolar disorder. J Bras Psiquiatr. 2016;65(1):9-16. doi: 10.1590/0047-2085000000097
46. de Sousa RT, Busnello JV, Forlenza OV, et al. Early improvement of psychotic symptoms with lithium monotherapy as a predictor of later response in mania. J Psychiatr Res. 2012;46(12): 1564-1568.
47. Alda M. Lithium in the treatment of bipolar disorder: pharmacology and pharmacogenetics. Mol Psychiatry. 2015;20(6):661-670.
48. Goes FS, McGrath J, Avramopoulos D, et al. Genome-wide association study of schizophrenia in Ashkenazi Jews. Am J Med Genet B Neuropsychiatr Genet. 2015;168(8):649-659.
49. Sekar A, Bialas AR, de Rivera H, et al; SchizophreniaWorking Group of the Psychiatric Genomics Consortium. Schizophrenia risk from complex variation of complement component 4. Nature. 2016;530(7589):177-183.
50. Del Vecchio M, Farzati B, Maj M, Minucci P, Guida L, Kemali D. Cell membrane predictors of response to lithium prophylaxis of affective disorders. Neuropsychobiology. 1981;7(5):243-247.
51. Maj M, Del Vecchio M, Starace F, Pirozzi R, Kemali D. Prediction of affective psychoses response to lithium prophylaxis: the role of socio-demographic, clinical, psychological and biological variables. Acta Psychiatr Scand. 1984;69 (1):37-44.
52. Perris C, Strandman E, Welby L. HL-A antigens and the response to prophylactic lithium. Neuropsychobiology. 1979;5(2):114-118.
53. Yu Z, Ono C, Aiba S, et al. Therapeutic concentration of lithium stimulates complement C3 production in dendritic cells and microglia via GSK-3 inhibition. Glia. 2015;63(2):257-270.
54. Li X, Bijur GN, Jope RS. Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection. Bipolar Disord. 2002;4(2):137-144.
55. Martin M, Rehani K, Jope RS, Michalek SM. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3Nat Immunol. 2005;6(8):777-784.
56. Upthegrove R, Manzanares-Teson N, Barnes NM. Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis. Schizophr Res. 2014;155(1-3):101-108.
57. M ler N, Weidinger E, Leitner B, Schwarz MJ. The role of inflammation in schizophrenia. Front Neurosci. 2015;9:372.
58. Rosenblat JD, McIntyre RS. Bipolar disorder and inflammation. Psychiatr Clin North Am. 2016;39 (1):125-137.
59. Guloksuz S, Altinbas K, Aktas Cetin E, et al. Evidence for an association between tumor necrosis factor-alpha levels and lithium response. J Affect Disord. 2012;143(1-3):148-152.
60. Giambelluca MS, Bertheau-Mailhot G, Laflamme C, Rollet-Labelle E, Servant MJ, Pouliot M. TNF-α expression in neutrophils and its regulation by glycogen synthase kinase-3: a potentiating role for lithium. FASEB J. 2014;28(8): 3679-3690.
61. Petersein C, Sack U, Mergl R, et al. Impact of lithium alone and in combination with antidepressants on cytokine production in vitro. J Neural Transm (Vienna). 2015;122(1):109-122.
62. Rowse AL, Naves R, Cashman KS, et al. Lithium controls central nervous system autoimmunity through modulation of IFN-? signaling. PLoS One. 2012;7(12):e52658.
63. Rapaport MH, Manji HK. The effects of lithium on ex vivo cytokine production. Biol Psychiatry. 2001;50(3):217-224.
64. Boufidou F, Nikolaou C, Alevizos B, Liappas IA, Christodoulou GN. Cytokine production in bipolar affective disorder patients under lithium treatment. J Affect Disord. 2004;82(2):309-313.
65. Guloksuz S, Cetin EA, Cetin T, Deniz G, Oral ET, Nutt DJ. Cytokine levels in euthymic bipolar patients. J Affect Disord. 2010;126(3):458-462.
66. Mertens J, Wang QW, Kim Y, et al; Pharmacogenomics of Bipolar Disorder Study. Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder [published correction appears in Nature. 2016;530(7589):242]. Nature. 2015;527(7576): 95-99.
67. Jaer M, Haack S, Becker T, Frasch K. Schizoaffective disorder-an ongoing challenge for psychiatric nosology. Eur Psychiatry. 2011;26(3): 159-165.
68. Purcell SM, Wray NR, Stone JL, et al; International Schizophrenia Consortium. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009; 460(7256):748-752.